Friday Satellite Symposia
Diseases
Grand Ballroom, 4
(Omni San Diego)
Chair:
Neil Love, MD, Research To Practice
Disclosures:
No relevant conflicts of interest to declare.
Speakers:
Jeremy S. Abramson, MD, Massachusetts General Hospital Cancer Center
,
Stephen M Ansell, MD, PhD, Mayo Clinic
,
Nancy L. Bartlett, MD, Washington University School of Medicine
,
Jonathon B. Cohen, MD, MS, Winship Cancer Institute, Emory University
,
Jonathan W. Friedberg, MD, MMSc, University of Rochester
and
Brad S. Kahl, MD, Washington University School of Medicine in St. Louis
Disclosures:
Abramson: Genmab: Consultancy; Genentech: Consultancy; Epizyme: Consultancy; Incyte: Consultancy; Interius: Consultancy; Janssen: Consultancy, Honoraria; Kymera: Consultancy; Kite Pharma: Consultancy; Lilly: Consultancy; Merck: Research Funding; MorphoSys: Consultancy; Celgene: Consultancy; Century Therapeutics: Consultancy; Cellectar Biosciences: Consultancy; Takeda: Consultancy; Mustang Bio: Consultancy, Research Funding; Caribou Biosciences: Consultancy; Seagen Inc.: Research Funding; AI Therapeutics: Research Funding; Regeneron: Consultancy, Honoraria; Ono Pharma: Consultancy; Novartis: Consultancy; Karyopharm Therapeutics: Consultancy; C4 Therapeutics: Consultancy; EMD Serono: Consultancy; Alimera Sciences: Consultancy; Bluebird Bio: Consultancy; BMS: Consultancy, Honoraria, Research Funding; BeiGene: Consultancy; AstraZeneca: Consultancy, Honoraria; AbbVie: Consultancy. Ansell: ADC Therapeutics, Affimed, Bristol-Myers Squibb Company, Pfizer Inc, Regeneron Pharmaceuticals Inc, Seagen Inc, Takeda Pharmaceuticals USA Inc.: Other: Contracted Research. Bartlett: ADC Therapeutics, Autolus, Bristol-Myers Squibb Company, Celgene Corporation, Forty Seven Inc, Immune Design, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Pharmacyclics LLC, an AbbVie Company, Genentech, a member of the Roche Group, Seagen Inc, Tak: Other: Contracted Research; ADC Therapeutics, Genentech, a member of the Roche Group, Seagen Inc: Other: Advisory Committee; Foresight Diagnostics: Other: Advisory Board; Kite: Other: Advisory Board; Millinneum: Research Funding. Cohen: BMS/Celgene: Research Funding; BioInvent: Research Funding; Lam Therapeutics: Research Funding; Genentech: Research Funding; Novartis: Research Funding; Takeda,: Research Funding; ADCT: Consultancy; AstraZeneca: Consultancy, Research Funding; Abbvie: Consultancy; Janssen: Consultancy; BeiGene: Consultancy; Loxo/Lilly: Consultancy, Research Funding.
On Demand program will be available here soon. For questions, please reach out to the managing company contact from Research to Practice, listed below.
This CME program, offered for in-person and virtual attendees, will focus on the management of follicular, mantle cell and Hodgkin lymphoma. Six investigators will serve as faculty and the program will be moderated by Dr Neil Love, president of Research To Practice (RTP). Prior to the program, RTP will recruit 15 investigators, who, in addition to the participating faculty, will be asked to complete a case-based survey intended to illuminate their general practice patterns. In addition, RTP will recruit 3 “non-faculty member” investigators to participate in video recorded interviews with Dr Neil Love in which they will provide an explanation/justification for their responses to this same survey and share the scientific rationale.
At the live event, for each module, Dr Love will present results from the survey, followed by video excerpts from the non-faculty member interviews. The faculty panelists will then be asked to register their level of agreement/disagreement with their colleagues’ answers and provide perspectives on their own responses. Each faculty will deliver a brief PPT presentation focused on reviewing recently published research data and ongoing clinical trials. Clinicians in attendance will have the opportunity to provide feedback on the same survey and present their own questions for discussion.